IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population

Liver International

Volumn 32, Issue 3, 2012, Pages 476-486

  Cavalcante, Lourianne N ^a,b   Abe Sandes, Kiyoko ^a,c   Angelo, Ana Luiza D ^a   Machado, Taisa M B ^a   Lemaire, Denise C ^a,d   Mendes, Carlos M C ^a   Pinho, João R ^e   Malta, Fernanda ^e   Lyra, Luiz G C ^a,b   Lyra, André C ^a,b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b HOSPITAL SÃO RAFAEL   (Brazil)

^c UNIVERSIDADE DO ESTADO DA BAHIA   (Brazil)

^d ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antiviral therapy; Genetic ancestry; Hepatitis C; IL28B; Polymorphism; Single nucleotide

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AFRICAN AMERICAN; AMERICAN INDIAN; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG TREATMENT FAILURE; ETHNICITY; FEMALE; GENETIC MARKER; GENOTYPE; HEPATITIS C; HEREDITY; HUMAN; MALE; NEGRO; RELAPSE; TREATMENT RESPONSE;

CASE-CONTROL STUDIES; CONTINENTAL POPULATION GROUPS; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84856757518     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02653.x     Document Type: Article

References (38)

1. Ray KW. Global epidemiology and burden of hepatitis C. Microbes Infect 2002; 4: 1219-25.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
5. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
6. Seeff LB, Hoofnagle JH. Appendix: the National Institutes of Health Consensus Development Conference management of hepatitis C 2002. Clin Liver Dis 2003; 7: 261-87.
7. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-7.
8. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002; 97: 700-6.
9. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
10. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
11. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
12. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
13. Stattermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344-50.
14. Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-92.
15. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
16. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45.
17. Jorns C, Holzinger D, Thimme R, et al. Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-alpha. J Med Virol 2006; 78: 74-82.
18. Naito M, Matsui A, Inao M, et al. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 2005; 40: 381-8.
19. Carneiro VL, Lemaire DC, Bendicho MT, et al. Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders. Liver Int 2010; 30: 567-73.
20. Yan KK, Guirgis M, Dinh T, et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol 2008; 14: 3416-20.
21. Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-7.
22. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 1996; 24: 289-93.
23. Shriver MD, Smith MW, Jin L, et al. Ethnic-affiliation estimation by use of population-specific DNA markers. Am J Hum Genet 1997; 60: 957-64.
24. Parra EJ, Marcini A, Akey J, et al. Estimating African American admixture proportions by use of population-specific alleles. Am J Hum Genet 1998; 63: 1839-51.
25. Batzer MA, Stoneking M, Alegria-Hartman M, et al. African origin of human-specific polymorphic Alu insertions. Proc Natl Acad Sci USA 1994; 91: 12288-92.
26. Krieger H, Morton NE, Mi MP, et al. Racial admixture in north-eastern Brazil. Ann Hum Genet 1965; 29: 113-25.
27. Parra FC, Amado RC, Lambertucci JR, et al. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 2003; 100: 177-82.
28. Thomas-Domenech JM, Padilla-Bolivar A. Atlas de las Razas Humanas. 1st ed. Barcelona: Jover, 1964.
29. Brazilian Institute of Geography and Statistics (IBGE). População residente, por cor ou raça, segundo as Grandes Regiões e as Unidades da Federação - 2000, 2000 Available at (accessed 20 September 2011).
30. Raymond M, Rousset F. GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism. J Hered 1995; 86: 248-9.
31. Chakraborty R. Gene identity in racial hybrids and estimation of admixture rates. In: Ahuja Y, Neel JV, eds. Genetic Microdifferentiation in Human and Other Animal Populations. Delhi, India: Anthropological Association, Delhi University Anthropology Department, 1985; 171-80.
32. Divers J, Vaughan LK, Padilla MA, et al. Correcting for measurement error in individual ancestry estimates in structured association tests. Genetics 2007; 176: 1823-33.
33. Abe-Sandes K, Silva WA Jr, Zago MA. Heterogeneity of the Y chromosome in Afro-Brazilian populations. Hum Biol 2004; 76: 77-86.
34. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-14.
35. Sarrazin C, Susser S, Doehring A, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-21.
36. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 33-7.
37. Yu ML, Huang CF, Huang JF, et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53: 7-13.
38. Shriver MD, Parra EJ, Dios S, et al. Skin pigmentation, biogeographical ancestry and admixture mapping. Hum Genet 2003; 112: 387-99.